Sir, Successful ART has substantially increased the life expectancy of HIV patients; 1,2 however, ART-related long-term toxicities have led to the emergence of novel treatment strategies, such as NRTI-free dual therapy. The combination of the integrase inhibitor dolutegravir and the ritonavir-boosted PI darunavir may play a key role in this setting. Therefore, the potent integrase strand transfer inhibitor dolutegravir, 3 in combination with the boosted PI with the highest known resistance barrier, darunavir, 4 might offer a potentially tolerable, safe and effective ART strategy. No data for once-daily 50mg dolutegravir in combination with 800/100mg darunavir/ritonavir are available to date. 5 The aim of the present study was thus to investigate the efficacy and pharmacokinetics, as well as to determine the drug combination effect profile, after a switch to this dual regimen in virologically controlled, pretreated patients. We performed a large prospective, interventional, randomized, controlled, multicentre study (DUALIS, Eudra-CT: 2015-000360-34, 320 subjects targeted) to assess the safety and efficacy of a combination therapy of once-daily 50mg dolutegravir with 800/100mg darunavir/ritonavir (the study was approved by the ethics committee at University Hospital Klinikum rechts der Isar, Munich, Germany; approval no. 162/15AF). A pharmacokinetic sub-study was performed at 5/29 centres between September 2015 and July 2016. After obtaining written informed consent, serum blood draws for the pharmacokinetic sub-study (PK I) took place at a single study visit, i.e. 28+4days after switching, and occurred prior to and 1, 2, 4, 8 and 12h after observed intake of a single dose of 50mg dolutegravir in combination with 800/100mg darunavir/ritonavir taken with food. Blood samples were centrifuged at 4500rpm for 10min and plasma samples were stored at #80 C; dolutegravir and darunavir concentrations were measured by HPLC; 6,7 internal standards were carbamazepine for darunavir and quinoxaline for dolutegravir (the lower limit of quantification was 125ng/mL for darunavir and 150ng/mL for dolutegravir and the limits of detection were 2 and 1.8ng/mL for dolutegravir and darunavir, respectively). All data are provided as the median (IQR) if not stated otherwise. Parameters that were determined include AUC 0-12 , C max , C trough , apparent oral clearance and apparent terminal halflife (t1 =2 ); AUC was calculated using cubic splines. For evaluating the statistical significance of the changes from baseline in safety laboratory parameters (liver function, renal and haematological parameters), the two-sided Wilcoxon signed-rank test for paired samples was used.
Ten subjects (7 males and 3 females) with a median (IQR) age of 46 (37-50)years, BMI of 24. Concerning pharmacokinetic analysis, 9 out of 10 patients had detectable dolutegravir and darunavir plasma concentrations prior to their intake (C trough ). One patient (a 50-year-old man) had undetectable darunavir C trough and very low dolutegravir C trough . However, after direct observation of drug intake, dolutegravir and darunavir concentrations were within expected ranges without evidence of malabsorption. Overall, median (IQR) C trough values were 637 (483-923)ng/mL for dolutegravir and 1245 (575-1818)ng/mL for darunavir. Measured C max values were 3427 (2964-4048)ng/mL for dolutegravir and 6170 (5708-8950)ng/mL for darunavir (Figure 1 ). Median concentrations after 1, 2, 4, 8 and 12h were 3053, 3020, 2679, 1846 and 1359ng/mL for dolutegravir and 5271, 6125, 4771, 2699 and 2199ng/mL for darunavir, respectively. C trough remained 4-to 17-fold above the protein-adjusted IC 90 (64ng/mL) for dolutegravir 8 and 1-to 22-fold above the protein-adjusted EC 90 (200ng/mL) for darunavir 9 (excluding the patient with undetectable darunavir and low dolutegravir C trough ). Median (IQR) AUC 12 was 26809 (22441-28459)ngÁh/mL for dolutegravir and 49920 (36729-56234)ngÁh/mL for darunavir. Documented co-medication had no known potential impact on dolutegravir or darunavir concentration.
Data from this pharmacokinetic study demonstrate adequate steady-state drug concentrations of dolutegravir and darunavir in all adherent patients. Except for one patient with adherence issues on the day prior to pharmacokinetic sampling, C trough values for dolutegravir and darunavir were above the protein-adjusted IC 90 and EC 90 values, respectively, and these patients reported 100% adherence within the study period. Data from the drug-drug interaction between boosted darunavir (600mg every 12h) and dolutegravir (30mg once daily) were investigated in an open-label study in healthy volunteers and dolutegravir AUC 24 , C max and C trough decreased 22%, 11% and 38%, respectively. 5 This decrease in dolutegravir parameters in healthy volunteers was not considered to be clinically relevant by the authors. Our study confirmed this hypothesis and demonstrated adequate plasma concentrations following the once-daily dosing of 800/100mg darunavir/ritonavir plus 50mg dolutegravir. No significant change in liver, renal or haematological function was reported.
